Radical external beam re‐irradiation in the treatment of recurrent head and neck cancer: Critical review

Švajdová, Michaela; Dubinský, P.; Kazda, Tomáš

doi:10.1002/hed.26485

Cited by 15 publications

(12 citation statements)

References 94 publications

(248 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,7 Additionally, the risk of developing a second primary head and neck malignant tumor is approximately 15% to 40%. 7,8 The treatment of choice for recurrent or second primary HNSCC in previously irradiated areas is surgery; however, only 20% of these relapses are operable. 8 Therefore, external beam radiotherapy is often implemented in this setting, including intensity-modulated radiation therapy, stereotactic body radiotherapy, and proton therapy.…”

Section: Recurrent and Metastatic Hnsccmentioning

confidence: 99%

“…7,8 The treatment of choice for recurrent or second primary HNSCC in previously irradiated areas is surgery; however, only 20% of these relapses are operable. 8 Therefore, external beam radiotherapy is often implemented in this setting, including intensity-modulated radiation therapy, stereotactic body radiotherapy, and proton therapy. 7 In the past, brachytherapy had been used in the recurrent setting.…”

Section: Recurrent and Metastatic Hnsccmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer

Ritter

Koirala

Wieland

et al. 2023

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

ImportanceSquamous cell carcinoma of the head and neck (HNSCC) is prevalent globally and in the US. Management, particularly after disease recurrence, can be challenging, and exploring additional treatment modalities, such as therapeutic cancer vaccines, may offer an opportunity to improve outcomes in this setting.ObservationsThis review provides an overview of the clinical efficacy of different treatment modalities that are currently available for the treatment of recurrent and metastatic HNSCC, including checkpoint inhibitors and targeted therapies, with a detailed summary of the numerous T-cell vaccines that have been studied in the setting of HNSCC, as well as a detailed summary of B-cell therapeutic vaccines being investigated for various malignant tumors.Conclusions and RelevanceThe findings of this review suggest that several therapeutic T-cell and B-cell vaccines, which have been recently developed and evaluated in a clinical setting, offer a promising treatment modality with the potential to improve outcomes for patients with recurrent and metastatic HNSCC.

show abstract

Section: Recurrent and Metastatic Hnsccmentioning

confidence: 99%

Section: Recurrent and Metastatic Hnsccmentioning

confidence: 99%

Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer

Ritter

Koirala

Wieland

et al. 2023

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

“…Therefore, SBRT possesses the advantages of shorter treatment duration and avoids interruption of systemic treatment. SBRT can generate a steep dose gradient between target tissues and surrounding healthy tissues, thereby reducing the overall radiation dose to critical organs at proximity to the target volume [18,19]. The results of recent studies on the treatment of rHNC with SBRT are summarized in Table 1 [3,8,9,17,[20][21][22][23].…”

Section: Sbrtmentioning

confidence: 99%

Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review

Jiang

Qiu

et al. 2022

J Transl Med

View full text Add to dashboard Cite

Background In the management of head and neck cancer (HNC) patients, local recurrence is a common cause of treatment failure. Only a few patients with recurrent HNC (rHNC) are eligible for salvage surgery and the majority of patients receive systemic therapy and radiotherapy. In recent years, with the development of irradiation technology, radiotherapy for rHNC patients has markedly attracted clinicians’ attention and its therapeutic effects on patients with end-stage cancer are worthy of investigation as well. Methods Several studies have investigated the role of radiotherapy in the treatment of rHNC patients. We reviewed retrospective reports and prospective trials published in recent decades that concentrated on the management of rHNC. Results A growing body of evidence supported the application of irradiation to rHNC patients. According to the results of this review, current radiotherapy could achieve a better efficacy with a lower incidence of toxicity. Conclusion Radiotherapy is a promising treatment for rHNC patients.

show abstract

“…Thus, radiation oncologists strive to minimize dose overlap with the previously irradiated target volume when planning a re-irradiation. [28][29][30] Here, proton therapy has an inherent advantage. 31) The MD Anderson Cancer Center (MDACC) reported the results of an initial study on 60 patients who were re-irradiated with proton therapy for HNC.…”

Section: Re-irradiation In Hncmentioning

confidence: 99%

Proton Therapy for Head and Neck Cancer: Current Clinical Applications and Future Direction

오¹

2021

Korean J Head Neck Oncol

View full text Add to dashboard Cite

Intensity-modulated radiation therapy (IMRT) using X-rays is a standard technique implemented for treating head and neck cancer (HNC). Compared to 3D conformal RT, IMRT can significantly reduce the radiation dose to surrounding normal tissues by using a highly conformal dose to the tumor. Proton therapy is a type of RT that uses positively charged particles named protons. Proton therapy has a unique energy deposit (i.e., Bragg peak) and greater biological effectiveness than that of therapy using X-rays. These inherent properties of proton therapy make the technique advantageous for HNC treatment. Recently, advanced techniques such as intensity-modulated proton therapy have further decreased the dose to normal organs with a higher conformal dose to the tumor. The usage of proton therapy for HNC is becoming widespread as the number of operational proton therapy centers has increased worldwide. This paper aims to present the current clinical evidence of proton therapy utility to HNC clinicians through a literature review. It also discusses the challenges associated with proton therapy and prospective development of the technique.

show abstract

Radical external beam re‐irradiation in the treatment of recurrent head and neck cancer: Critical review

Cited by 15 publications

References 94 publications

Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer

Therapeutic Cancer Vaccines for the Management of Recurrent and Metastatic Head and Neck Cancer

Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review

Proton Therapy for Head and Neck Cancer: Current Clinical Applications and Future Direction

Contact Info

Product

Resources

About